Cardiol Therapeutics Inc. (CRDL) Form 6-K — Sep 23, 2026
Cardiol Therapeutics enrolled 110 patients in its Phase III MAVERIC trial of CardiolRx™ for recurrent pericarditis, hitting its original target ahead of end-of-September guidance. The MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients after a blinded review showed fewer-than-expected pericarditis recurrences — an observation management views as encouraging since it may reflect drug effect. The tradeoff is timing: topline results now expected mid-2027 versus prior Q1 2027 guidance, though existing capital funds completion with runway into Q1 2028.
Key figures
- Cash runway
- into Q1 2028
- Maaveric enrollment
- 110
- Topline data timing
- mid-2027
- Prior topline guidance
- Q1 2027
- Expanded enrollment target
- up to 150 patients
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.